WeVote
Log In

Bill

Bill

HR 4581

340B PATIENTS Act of 2025

119th Congress Introduced by Kathy Castor and 15 co-sponsors

The 340B PATIENTS Act enhances access to affordable medications for low-income patients by supporting healthcare providers in the 340B Drug Pricing Program.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 4581

Summary of HR 4581 - 340B PATIENTS Act of 2025

Overview

The 340B PATIENTS Act of 2025 (HR 4581) is a legislative proposal aimed at enhancing access to essential medications and treatments for patients enrolled in the 340B Drug Pricing Program. This program is designed to allow certain healthcare providers to purchase outpatient drugs at reduced prices, thereby improving healthcare access for low-income and uninsured individuals.

Purpose and Intent

The primary intent of the 340B PATIENTS Act is to strengthen the 340B program, ensuring that healthcare providers can continue to serve vulnerable populations effectively. The bill seeks to address challenges faced by these providers in maintaining access to affordable medications, thereby supporting public health initiatives and improving patient outcomes.

Key Provisions

While the specific provisions of the bill have not been detailed in the provided information, the following are anticipated based on the bill's title and context:

  • Enhanced Funding: The bill may propose increased funding or financial support mechanisms for healthcare providers participating in the 340B program.
  • Regulatory Adjustments: It could include provisions to streamline regulations governing the 340B program, making it easier for providers to access discounted medications.
  • Patient Support Initiatives: The legislation may introduce initiatives aimed at improving patient education and outreach regarding available treatments under the 340B program.

Affected Parties

The following groups are likely to be impacted by the 340B PATIENTS Act:

  • Healthcare Providers: Hospitals and clinics that participate in the 340B program will benefit from enhanced support and resources.
  • Patients: Low-income and uninsured individuals who rely on these providers for affordable medications will have improved access to necessary treatments.
  • Pharmaceutical Companies: Changes to pricing and access regulations may affect how pharmaceutical companies engage with the 340B program.

Legislative Process and Timeline

  • Introduced: The bill was introduced in the House on July 22, 2025.
  • Committee Referral: It has been referred to the House Committee on Energy and Commerce for further consideration.
  • Cosponsors: The bill has garnered support from multiple cosponsors, indicating a collaborative effort to advance its objectives.

Related Legislation

The 340B PATIENTS Act has a companion bill, S 2372, which is likely being considered in the Senate. This parallel effort may facilitate a more comprehensive legislative approach to the issues addressed in HR 4581.

Conclusion

The 340B PATIENTS Act of 2025 represents a significant step towards reinforcing the 340B Drug Pricing Program, aiming to ensure that healthcare providers can continue to deliver essential medications to underserved populations. As the bill progresses through the legislative process, further details on specific provisions and impacts will become clearer.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.